Stifel Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $2.5
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
Stifel analyst Paul Matteis initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Target of $2.5.
Stifel analyst Paul Matteis initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Target of $2.5.